Cyclin A/cdk2 is active during S and G2 phases of the cell cycle, but its regulation and function during G2 phase is poorly understood. In this study we have examined the regulation of cyclin A/cdk2 activity during normal G2 phase progression and in genotoxin-induced G2 arrest. We show that cyclin A/cdk2 is activated in early G2 phase by a cdc25 activity. In the G2 phase checkpoint arrest initiated in response to various forms of DNA damage, the cdc25-dependent activation of both cyclin A/cdk2 and cyclin B1/cdc2 is blocked. Ectopic expression of cdc25B, but not cdc25C, in G2 phase arrested cells eciently activated both cyclin A/cdk2 and cyclin B1/cdc2. Finally, we demonstrate that the block in cyclin A/cdk2 activation in the G2 checkpoint arrest is independent of ATM/ATR. We speculate that the ATM/ ATR-independent block in G2 phase cyclin A/cdk2 activation may act as a further layer of checkpoint control, and that blocking G2 phase cyclin A/cdk2 activation contributes to the G2 phase checkpoint arrest. Oncogene (2001) 20, 921 ± 932.
Introduction
In eukaryotes, cell division is driven by the sequential activation of a series of cyclin-dependent kinases (cdks) (Morgan, 1997) . The sequence and timing of activation of the dierent cdk isoforms determines the order of the major cell cycle transitions: onset of DNA replication, and entry into mitosis. This process is subject to a complex network of redundant control mechanisms, each dependent on the execution of a prior necessary cell cycle event, thereby ensuring the completion of one cell cycle phase before progression to the next (Morgan, 1997) . Checkpoint pathways exist to sense disruption of the normal cell cycle dependencies, particularly those that ensure completion of DNA replication and integrity of the genome prior to the onset of mitosis. The checkpoints function to aect cell cycle arrest until the perturbation is corrected, thereby linking surveillance, signaling, and repair mechanisms to those that drive the cell cycle itself (Elledge, 1996) .
The mechanisms controlling cell cycle progression and checkpoint function are highly conserved throughout eukaryotic evolution, particularly the mechanisms that regulate entry into mitosis. In yeast, entry into mitosis is regulated at the level of cyclin B/cdc2 activation, which in turn is regulated by a single cdc25 isoform (Morgan, 1997; O'Connell et al., 2000) . A more complex system of controls has evolved in mammalian cells, where two cyclin/cdk complexes, cyclin A and cyclin B/cdks have mitotic functions. The function of cyclin B/cdc2 is conserved, but the role of cyclin A/cdk complexes during G2/M progression remains obscure. Cyclin A associates with two cdks during G2/M, cdk2 and cdc2, with cyclin A/cdk2 being the most abundant and active of these complexes (Pagano et al., 1992 (Pagano et al., , 1993 Rosenblatt et al., 1992) . Cdk2 also associates with cyclin E, but this complex is restricted to late G1 and S phase, with little or no complex present in late S and G2 phase cells (Dulic et al., 1992; Ko et al., 1992) . The activation of cyclin A/ cdk2 is biphasic, with a pool of cyclin A/cdk2 activated early in S phase, and a larger pool activated in G2 phase, prior to the activation of cyclin B/cdc2 at the G2/M transition Pagano et al., 1992 Pagano et al., , 1993 Rosenblatt et al., 1992) . The mechanism of these activation events appears to be through the dephosphorylation of the inhibitory tyrosine 15 residue on cdk2 . The early S phase activation is catalysed by cdc25A (Blomberg and Homann, 1999; Sexl et al., 1999) , but there is little evidence of a role for this isoform later in the cell cycle. Cdk2 is maximally phosphorylated on tyrosine 15 in late S/ G2 phase , but a direct demonstration of the involvement of a cdc25 activity in the activation of this G2 phase complex in vivo, and the identity of the cdc25, has not been reported. Two cdc25 isoforms, cdc25B and cdc25C, have roles in G2/M progression (Millar et al., 1991; Gabrielli et al., 1996; Lammer et al., 1998) , but only cdc25B eciently catalysed the activation of cyclin A/cdk2 in vitro (Gabrielli et al., 1997a) . Cyclin A/cdk2 has an essential S phase function, and its G2 phase activity appears to be required for entry into mitosis (Pagano et al., 1992; Furuno et al., 1999) . The small pool of cyclin A/ cdc2 is activated at the G2/M phase transition with cyclin B/ cdc2 (Pagano et al., 1992) . The function of this complex is unclear, although it has been shown to control the timing of cdc25B destruction (Baldin et al., 1997) , suggesting it may play a more general role in the timing of exit from mitosis.
The checkpoint pathways that monitor the completion of DNA replication and survey the genome for DNA damage impose a cell cycle arrest by blocking cdk activity. In mammalian cells, the DNA damage checkpoints can arrest cell in G1 and G2 phases. The G1 phase DNA damage checkpoint has been shown to involve the p53-dependent activation of p21 expression, which arrests cell cycle progression by forming complexes with the G1 cdks and inhibiting their activity (Elledge, 1996) . If DNA damage occurs after G1 phase or in p53-null cells, the G2 checkpoint is accentuated. The ultimate target of this checkpoint is the mitotic regulator cyclin B/cdc2, and DNA damage induced by a variety of dierent agents results in the accumulation of the inactive Tyr15 phosphorylated cdc2 containing form of the complex, thereby preventing entry into mitosis (Lock, 1992; Herzinger et al., 1995; Jin et al., 1996) . This G2 checkpoint arrest and accumulation of the inactive Tyr15 phosphorylated cyclin B/cdc2 has also been demonstrated in ®ssion yeast . In this organism, the checkpoint has been shown to be dependent on the Rad3/Rad24/Chk1 signaling cascade, which targets cdc25 and wee1 activities, thereby maintaining phosphorylation of Tyr15 and preventing activation of cdc2 O'Connell et al., 1997; Raleigh and O'Connell, 2000) . This checkpoint pathway is conserved in mammalian cells, and though its regulation and function are clearly more complex than in yeast, the fundamental mechanism underlying the checkpoint arrest appears to be identical (O 'Connell et al., 2000) .
In this paper we have investigated the regulation of cyclin A/cdk2 activity during normal G2/M progression and in cells arrested at the G2 checkpoint after treatment with sublethal doses of a range of genotoxins. We demonstrate that cyclin A/cdk2 is activated by a cdc25 activity in early G2 phase and that this activation is blocked in G2 arrested cells. Our data also suggests that inhibiting cyclin A/cdk2 activation contributes to the maintenance of a G2 phase arrest in response to DNA damage.
Results

Cdc25-dependent activation of cyclin A/cdk2 in early G2 phase
The activity of cyclin A/cdk2 during the cell cycle is biphasic, with a small pool active during S phase and a second, larger pool active during G2 phase. In HeLa cells synchronised by a thymidine block protocol, cdk2-associated histone H1 kinase activity was relatively constant through S phase, then increased rapidly as cells entered G2 phase, preceding the activation of cyclinB1/cdc2 at the G2/M transition ( Figure 1a) . The histone H1 kinase activity of cdk2 immunoprecipitates from cells in late S/early G2 phase (6 ± 7 h after release from the thymidine block) was activated in vitro by treatment with bacterially expressed cdc25B, suggesting that the increase in cdk2 activity in G2 phase may be due to cdc25-dependent activation (Figure 1b) .
To examine whether the activation of cyclin A/cdk2 in G2 phase was a cdc25-dependent process, we have attempted to block G2 phase cdc25 activity. One approach was to transfect the dominant negative cdc25B CR/SK mutant into HeLa cells using the bicistronic expression vector pIRESpuro. The timing of cdc25B expression, its in vivo activity and ability to activate cyclin A/cdk2 in vitro (Gabrielli et al., 1997a) , suggested this isoform as candidate activator of the G2 phase cyclin A/cdk2, and we had previously shown that over expression of cdc25B CR/SK produces a G2 phase arrest Forrest et al., 1999) . The pIRESpuro vector allowed for rapid (24 h) selection of puromycin resistant transfected cells, and bicistronic expression of both puromycin resistance and cdc25B CR/SK mutant from the one mRNA (a) Samples of thymidine block synchronised HeLa cells were taken at the indicated times after release and assayed for cdk2 and cyclin B1 immunoprecipitate histone H1 kinase activity. (b) cdk2 immunoprecipitates from late S/G2 phase cells (6 ± 7 h after release from the thymidine block) were immunoblotted for cyclin A and cdk2, or treated with recombinant cdc25B in vitro either in the presence or absence of sodium vanadate to inhibit cdc25 activity, and the histone H1 kinase activity assayed ensured that all puromycin resistant cells were also expressing the dominant negative mutant. FACS analysis of the puromycin selected cells revealed an accumulation of G2/M phase cells in the cdc25B2 CR/ SK transfection whereas the empty vector transfected cells displayed a normal asynchronous distribution (Figure 2a ). This was corroborated by the elevated levels of cyclin A and cyclin B1, similar to those found in normal late S/early G2 phase cells (Figure 2b ). Cdc25C expression was unaected despite the high level of cdc25B2 CR/SK over expression. Histone H1 kinase activity associated with cdk2 immunoprecipitates from the puromycin selected populations of both the empty vector and cdc25B2 CR/SK transfected populations was low, but could be activated by treatment with recombinant cdc25B in vitro. The cdc25B2 CR/SK transfectants displayed a much higher level of activation than the vector control (Figure 2c ), consistent with the higher level of cyclin A expression (Figure 2b) , and similar to the degree of activation seen in normal S/G2 phase cells (Figure 1b ). Cdc25B2 CR/SK over expression also blocked the activation of cyclin B1/cdc2 (Figure 2b ).
The synthetic vitamin K analogue, compound 5 (Cpd5) is an irreversible inhibitor of the mammalian cdc25s in vitro, and blocks G1/S and G2/M progression (Tamura et al., 2000) . When compound 5 was added to thymidine block release synchronised HeLa cells in late S phase (6 h after release, see Figure 1a ), it blocked G2/M progression and activation of cyclin A/cdk2 normally observed at 10 h after release (Figure 3 ).
DNA damage blocks the G2 activation of cyclin A/cdk2
A range of genotoxins which cause dierent types of DNA lesions induce G2 arrest in cells and block the cdc25-dependent activation of cyclin B/cdc2 (Lock, 1992; Herzinger et al., 1995; Jin et al., 1996) , but their eect on the G2 phase cyclin A/cdk2 activity and activation was unknown. Here, three dierent DNA damaging agents, ultraviolet radiation (UV), etoposide and ionizing radiation (IR), whose modes of action range from double-strand breaks to thymidine dimer and photo adduct formation were used. Treatment of asynchronously growing cultures with each agent produced an accumulation in the G2/M phase population within 24 h, as assessed by¯ow cytometric analysis of DNA content (Figure 4a ). Each damaging agent was used at a dose that caused 520% loss of viability within the ®rst 48 h following treatment. Similar G2 phase arrests were observed in cultures synchronised in early S phase by thymidine blockrelease and treated with the same genotoxic agents during S phase (Figure 4b ).
The expression of the cyclins A and B1, cdc2, cdk2, and potential activators and inhibitors of these complexes were assessed in the p53-independent G2 Figure 3 Cdc25 inhibitor blocks G2 phase activation of cyclin A/cdk2. Thymidine block synchronised HeLa cells were harvested at either 6 h (S/G2) or at 10 h after release, either with (Cpd5) or without (G2/M) addition of 20 mM Cpd5 at 6 h. FACS analysis con®rmed the cell cycle status. Cdk2 immunoprecipitates were immunoblotted for their associated cyclin A levels (cyclin A shown by arrow, running just above the IgG heavy chain), and assayed for H1 kinase activity (H1K). This was representative of four independent experiments Oncogene G2 phase cyclin A/cdk2 activity S Goldstone et al arrest initiated in response to each agent, as was the activity of the G2 phase cyclin A/cdk2 complex. In UV and etoposide treated cells, cyclin A accumulated to levels similar to those in late S/early G2 cells, whereas in IR treated cells cyclin A levels increased over those in asynchronous cultures, but to levels below those in the other G2 arrested cells ( Figure 5 ). Interestingly, cyclin A accumulated to the same level in IR treated cells as the other genotoxin treated cells in synchronised cultures irradiated during S phase (see Figure 7c ). Cyclin B1 accumulated to S/G2 phase levels in each arrested population ( Figure 5 ). Cdc2 and its slower migrating Thr14, Tyr15 phosphorylated inactive isoforms were readily detected in normal S/G2 cells and in the damage-induced G2 arrested cultures, and correlated with the expression of cyclin B1 in each case ( Figure 5 ). The levels of cdk2 were unchanged in response to any DNA damaging agent ( Figure 5 ). The expression of cdc25B and cdc25C, activators of G2/M cyclin A/ and cyclin B/cdks, were also examined. Cdc25B was expressed in S/G2 phase cells Forrest et al., 1999) , and in all G2 arrested cultures at levels approaching those in normal late S/ early G2 cultures, although cdc25B levels were lower in IR treated cells, as seen for cyclin A ( Figure 5 ). Cdc25C levels were similar in each cell population. The levels of the cdk inhibitor proteins p16, p21 and p27 were examined. Expression levels of the cdk4/cdk6 speci®c inhibitor, p16, increased strongly following UV irradiation as reported previously (Wang et al., 1996; Milligan et al., 1998) , but not in response to any of the other genotoxic agents. Expression of the global cdk inhibitor p21 was not detected, and there was a small increase in the expression of p27 in response to IR ( Figure 5 ).
To analyse cyclin A/cdk2 complexes, the G2 phase samples were ®rst immunodepleted of cdc2 (490% depletion of cdc2; Figure 6a ) to remove the small quantity of cyclin A/cdc2 present in these samples. Cyclin A immunoprecipitates from the cdc2-depleted samples all contained elevated levels of cdk2 phosphorylated on the inhibitory tyrosine 15 residue, detected using a phosphotyrosine 15-speci®c antibody ( Figure 6b ). The levels of phosphotyrosine 15 corresponded to the levels of cyclin A and cdk2 in each immunoprecipitate. The low levels of cyclin A and cdk2 in the IR-treated sample re¯ected the reduced level of cyclin A in this sample ( Figure 5 ). To con®rm that the phosphotyrosine 15 staining was due to cdk2 and not due to residual cdc2, cyclin A immunoprecipitates were boiled with 1% SDS and the supernatant diluted then re-immunoprecipitated with an anti-cdk2 Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 arrested cells
Detection of the phosphotyrosine 15 form of cdk2 in normal and genotoxin arrested G2 phase cells prompted the examination of the activity of cdk2 complexes. Cyclin B1/cdc2 activity in these samples was also assessed as a measure of the G2 arrest achieved. In asynchronously growing, genotoxin treated cells, cyclin A/cdk2 complexes were in a low activity form that could be further activated by the recombinant cdc25B. The activated levels were similar to those in normal late S/early G2 phase cells, and approaching the maximal levels of G2/M phase cells (Figure 7a,b) . The greater degree of variability in the basal and cdc25B sensitive cyclin A/cdk2 activity in the etoposide treated samples was a consequence of the low concentrations of etoposide used. This concentration allowed cells to leak through the G2 arrest and into mitosis (De Souza et al., 2000) . Higher concentrations (600 ± 800 nM) reduced the basal activity to the same levels as S/G2 and UV-treated cells without eecting cyclin A levels (Figure 7c ) or cdc25-dependent activation (Figures 7d and 8 ). The lower levels of endogenous and cdc25B activated cyclin A/cdk2 in IR treated cells was consistent with the lower levels of cyclin A found in those cells ( Figure 5 ). Similar results were observed in synchronised cultures treated with the various genotoxic agents during S phase. In each case, cyclin A and cyclin B1 levels were similar to those seen in normal early G2 phase cells (Figure 7c ). Cyclin A/ cdk2 complexes isolated from the dierent treatment groups showed a low endogenous histone H1 kinase activity, which could be activated in vitro by recombinant cdc25B (Figure 7d ). In both asynchronous and synchronised normal and G2 arrested cultures, cyclin B1/cdc2 was essentially inactive, and was activated by recombinant cdc25B (Figure 7d ). As cyclin A/cdk2 could be activated by cdc25B in vitro, we were interested to test whether it could be activated in G2 phase arrested cells by simply over expressing the mitotic cdc25 isoforms. Etoposide treated, G2 arrested cells were transfected with constructs expressing either cdc25B or cdc25C under the control of the SRa promoter to achieve very high level over expression within 6 h of transfection ( Figure  8a ). Assay of the histone H1 kinase activity associated with cdk2 and cyclin B1 immunoprecipitates from the cdc25B2 transfected populations showed strong activation of both cdk2 and cyclin B1 kinases over the levels seen in empty vector controls, or in cells expressing the catalytically inactive CR/SK mutant cdc25B2 ( Figure  8b ). Similar results were obtained using a second cdc25B splice variant, cdc25B3, and with transfections into UV and IR treated, G2 arrested cells (data not shown). Transfected cdc25C was incapable of activating cyclin A/cdk2 and catalysed a weaker activation of cyclin B1/cdc2 compared to cdc25B2.
Activation of cyclin A/cdk2 in G2 arrested cells is independent of ATM/ATR Mechanistically, the activation of cyclin A/cdk2 in early G2 phase appeared to be similar to the activation of cyclin B1/cdc2 at G2/M. In G2 arrested cells, the blockade of cyclin B1/cdc2 activation can be overcome by caeine, which is an eective inhibitor of both ATM and ATR kinase activities (Blasina et al., 1999) . Given the blockade in cyclin A/cdk2 activation we observe in G2 arrested cells, we tested the eect of Figure 3a ), were immunoblotted for cyclin A, cdk2, and phosphotyrosine 15 form of cdk2 using a phosphotyrosine 15-speci®c antibody. (c) Cyclin A immunoprecipitates from similar lysates to those used in (b), were boiled to release associated proteins, and the supernatant re-immunoprecipitated for cdk2. The immunoprecipitated cdk2 was immunoblotted for cdk2 and phosphotyrosine 15 caeine on the activation of cyclin A/cdk2 in etoposide treated HeLa cells. Within 2 h of caeine addition, cyclin B1/cdc2 was almost fully activated, whereas no activation of cyclin A/cdk2 was observed (Figure 9 ). Similar results were obtained with UV treated HeLa cells (data not shown). We also examined the status of cyclin A/cdk2 complexes following genotoxin treatment of the ATM-mutant melanoma cell line HT144 (Ramsay et al., 1998) . Etoposide treatment of either asynchronously growing or hydroxyurea synchronised HT144 cells elicited a G2 phase arrest which was maintained for up to 24 h (Figure 10a ). Immunoblotting for cyclin B1 and the phosphotyrosine 15 form of cdc2 revealed the accumulation of these markers of G2 phase compared to the asynchronous cultures, in both the synchronised G2 phase and etoposide treated G2 arrested cells (Figure 10b) . Analysis of cyclin A/cdk2 complexes from cdc2 immunodepleted lysates (as in Figure 6a ), revealed similar levels of the phosphotyrosine 15 form of cdk2 in both normal G2 and G2 arrested samples (Figure 10c) . Interesting, although cdc25B activated the complex isolated from normal G2 Figure 7 Cdc25B activates cyclin A/cdk2 and cyclin B1/cdc2 complexes from G2 arrested cells. (a) Cdk2 immunoprecipitates from normal S/G2 or G2/M phase HeLa cells, or from G2 arrested cultures similar to those in Figure 4a , were incubated with GSTcdc25B2, either with or without sodium orthovanadate, and assayed for H1 histone kinase activity. The autoradiographs of the phosphorylated histone H1 are shown for representative cdk2 immunoprecipitates. (b) Cdk2-associated histone HI kinase activities relative to the cdc25B-treated S/G2 sample were quantitated for four independent experiments. (c) Expression levels of cyclin A and B1 in either asynchronously growing (AS), normal S/G2 phase cells, and G2 arrested cells after genotoxins treatment during S phase (similar to the cultures shown in Figure 4b ), were determined by Western blotting. (d) Cdk2 and cyclin B1 immunoprecipitates from similar cultures to those in (c) were incubated with GST-cdc25B2 either with or without sodium orthovanadate as described and assayed as in (a). The data shown here are representative of three independent experiments G2 phase cyclin A/cdk2 activity S Goldstone et al phase cells, the cyclin A/cdk2 from G2 arrested cells was inactive and insensitive to further activation ( Figure 10d ). Taken together, these experiments suggest that the block in cyclin A/cdk2 activation seen in response to genotoxin treatment is independent of ATM and ATR.
Over expression of cdk2AF results in loss of stable G2 arrest
Each of the DNA damaging agents tested imposed a G2 phase arrest characterised by a block in the cdc25-dependent activation of both cyclin A/cdk2 and cyclin B1/cdc2. To assess the requirement for the observed block in cyclin A/cdk2 activation for the integrity of the checkpoint arrest, HeLa cells were transiently transfected with either empty vector, cdk2 wild type (cdk2 wt) or cdk2AF in which the regulatory Thr14 and Tyr15 residues were mutated to Ala and Phe respectively . Following transfection, the cells were treated with genotoxin for 24 h then analysed by FACS. This protocol delivered high level expression of the ectopic cdk2 (Figure 11a ). Short term expression of either wild type or mutant cdk2 did not eect cell cycle distribution in asynchronously growing cultures (Figure 11b ), although the cdk2 AF expressing cells were lost after several days in culture as reported previously Jin et al., 1996) . Genotoxin treatment resulted in the normal G2 phase accumulation of both vector and cdk2wt transfected cells, indicating that these cells were checkpoint pro®cient (Figure 11b ). However, cdk2AF expressing cells did not display the expected accumulation of cells with 4N DNA, but there was no commensurate increase in the G1 population which would indicate bypass of the G2 arrest ( Figure 11b ). There was, however, a consistent loss of 20 ± 50% of the cdk2AF over expressing cells in the genotoxin treated cultures compared with the untreated controls. Microscopic inspection of the cdk2 over expressing cells immunostained for the over expressed cdk2, microtubules and DNA did not reveal any evidence of an aberrant mitotic phenotype, and addition of nocodazole to trap cells that bypass the G2 arrest in mitosis, did not produce a G2/M accumulation in the genotoxin treated, cdk2AF transfected cultures. This was not due to failure of the mitotic spindle assembly checkpoint, since cdk2AF over expressing cells showed normal G2/M accumulation with nocodazole treatment (data not shown). The loss of cdk2AF expressing cells with genotoxin treatment Figure 9 Caeine bypasses the block in cyclin B1/cdc2 activation, but has no eect on cyclin A/cdk2 activation. HeLa cells were arrested in G2 phase using etoposide, then 5 mM caeine was added to the culture media, and cells harvested at the indicated times after caeine addition. Cdk2 and cyclin B1 immunoprecipitates were treated with recombinant cdc25B in vitro with or without added vanadate, and the H1 kinase activity measured. The level of cyclin A and cyclin B1 in each immunoprecipitate is shown was rescued by the addition of 5 mM caeine which bypassed the G2 arrest (Figure 11c ), suggesting that precocious activation of cdk2 was toxic in G2 arrested cells.
Discussion
The existence of a G2 phase peak of cyclin A/cdk2 activity was reported almost a decade ago (Pagano et al., 1992; Rosenblatt et al., 1992 ), yet its regulation and function is still poorly understood. Here we have presented evidence that the activation of cyclin A/cdk2 in late S/early G2 phase is due to a cdc25 activity, and that this activation is blocked in G2 arrested cells. We ®nd that cyclin A/cdk2 complexes isolated from the dierent G2 arrested cell populations contain elevated levels of tyrosine 15 phosphorylated cdk2 and can undergo cdc25B-dependent activation in vitro and in vivo. The physiological activator of G2 phase cyclin A/ cdk2 is as yet unknown. A candidate for this role is cdc25B. The ability of over expressed cdc25B to activate cyclin A/cdk2 and cyclin B1/cdc2 in G2 arrested cells is consistent with the substrate speci®city de®ned for the recombinant protein in vitro, as is the inability of over expressed cdc25C to activate cyclin A/ cdk2 (Gabrielli et al., 1997a) . The relative eciencies of over expressed cdc25B and cdc25C in activating cyclin B1/cdc2 in vivo are in agreement with the observations of Karlsson et al (1999) who have reported that cdc25B was more ecient in promoting mitosis than cdc25C. Over expression of wild type cdc25C was also demonstrated to be inecient at bypassed the IRinduced G2 arrest, although the Ser216 mutant of cdc25C which abrogated 14-3-3 binding eciently bypassed the arrest (Peng et al., 1997) . The ®nding that over expressing a dominant negative mutant of cdc25B blocked G2 phase cyclin A/cdk2 activation, and that over expressing cdc25B, but not cdc25C activated cyclin A/cdk2 in G2 phase arrested cells supports a role for cdc25B in this activation event in vivo.
An unexpected ®nding from this work was that the type of DNA lesion appears to in¯uence the mechanism of the G2 arrest. For example, only UV induced p16 expression, which may be a lesion speci®c response contributing to the G2 arrest with this genotoxin (Milligan et al., 1998; Gabrielli et al., 1999) . IR treatment also produced a unique response in HeLa cells with increased p27 expression and moderately reduced cyclin A levels. In the melanoma cell line A2058 arrested in G2 phase by either etoposide or IR, the normal G2/M accumulation of both cyclin A and cyclin B1 was blocked (data not shown), whereas the cyclin levels were unaected in the UV induced G2 arrest (Gabrielli et al., 1997b) . A number of genes with CDE and CHR elements in their promotors, including cyclins A and B1, are transcriptionally down regulated in the G2 checkpoint response to DNA damage (Badie et al., 2000) , and this type of mechanism may be responsible for the reduction in cyclin levels observed. Another group has reported IR treated ®broblasts block in G2 with loss of cdk2 expression, and ectopic expression of cdk2 attenuated this G2 block (Walker et al., 1995) . These studies suggest that cells can utilise a range of mechanisms to impose a G2 arrest, the mechanisms being in¯uenced by the type of lesion, the p53 status of the cells and possibly even the cell lineage. However, a common theme is that in G2 phase arrested cells the G2 phase cyclin A/cdk2 activity is inhibited, be it by down regulating cyclin A and/or cdk2 expression, up regulating cdk2 inhibitors or as we G2 phase cyclin A/cdk2 activity S Goldstone et al demonstrate in this report, by blocking the cdc25-dependent activation of the complex. The involvement of other mechanisms in blocking G2 phase cyclin A/ cdk2 activity is exempli®ed by the inability of cdc25B to activate cyclin A/cdk2 from etoposide treated HT144 cells. The inhibition of cyclin A/cdk2 activity and activation parallels cyclin B/cdc2 regulation in the G2 checkpoint. Cyclin B expression can be down regulated or delayed (Maity et al., 1996; Innocente et al., 1999) , and regulation of the inhibitory Thr14 and Tyr15 phosphorylations by wee1/myt1 and cdc25 is a major control mechanism in the p53-independent G2 checkpoint (Jin et al., 1996; O'Connell et al., 2000).
Our experiments have indicated that the G2 phase cyclin A/cdk2 complex is a target of the G2 phase DNA damage response. The question arises: Is the block in G2 cyclin A/cdk2 activation/activity involved in the checkpoint response? Observations from a number of groups suggest a possible role for this complex in the G2 arrest. For example, over expression of p27 or p21 can impose a G2 phase arrest, with the cdk inhibitors primarily bound to the G2 phase cyclin A/cdk2 complex (Niculescu et al., 1998) . Interestingly, in the G2 arrested cells, cyclin B1/cdc2 complexes were also inactive and showed an accumulation of the phosphorylated inactive forms of cdc2, although little Figure 11 Expression of cdk2AF results in loss of stable G2 arrest (a) Asynchronously growing HeLa cells were transfected with either empty vector (vector), cdk2 wt or cdk2AF, and 8 h later treated either without (Con) or with etoposide (Etop.) and harvested 24 h later. The level of the over expressed cdk2 in untreated control transfections are shown. The ectopically expressed cdk2 was slower migrating due to the introduced HA tag. (b) Cdk2 over expressing cells were identi®ed by immuno¯uorescent staining with an anti-cdk2 antibody and¯uorescein-conjugated secondary antibody and discriminated by FACS due to their increased uorescence compared to the vector controls (region R2 in the dot plots). The DNA histogram of the over expressing cells is shown, with the exception of the vector controls, where the total population is shown. In each experiment, a total of 5610 4 cells were analysed. These data are representative of nine experiments. (c) In a similar experiment to those in (b), cdk2AF transfected cultures were treated with either etoposide or etoposide and 5 mM caeine and analysed after 24 h p21 was found associated with these complexes (Niculescu et al., 1998) . In a parallel study, high levels of p21 were associated with cyclin A/cdk2 in normal G2 ®broblasts, and p21 was proposed to integrate G2 checkpoint signals by regulating cyclin A/cdk2 activity and G2/M progression (Dulic et al., 1998) . In the p53-dependent response to DNA damage, p21 has been demonstrated to be essential for the maintenance of the G2 checkpoint arrest (Bunz et al., 1998) , with the likely target of p21 being the G2 phase cyclin A/cdk2 complex. Furuno et al (1999) have shown that microinjection of cyclin A/cdk2 complexes into G2 phase cells is sucient to induce premature mitosis, while blocking cyclin A/cdk2 function by injection of p21 delays entry into mitosis. These studies suggest that in normal cell cycle progression, G2 phase cyclin A/cdk2 activity promotes progression into mitosis, and that blocking cyclin A/cdk2 activity in the G2 checkpoint may be involved in maintaining the cell cycle arrest.
We have demonstrated that cyclin B1/cdc2 can be activated independently of cyclin A/cdk2 by using caeine to inhibit ATM/ATR in G2 arrested cells, and over expressing cdk2AF in G2 arrested appears to be insucient to for progression into mitosis. This data con®rms the reported inability of the cdk2AF mutant to overcome the IR induced G2 arrest (Jin et al., 1996) . Together with the ability of caeine to release only cyclin B/cdc2 from the activation block, these observations point to ATM/ATR directly blocking cyclin B/ cdc2 activation in the checkpoint arrest. However, if cyclin A/cdk2 is required for normal G2/M progression as suggested by the observations discussed above, blocking this activity would contribute to the G2 phase arrest. The cdk2AF over expression experiments demonstrate that precocious activation of cyclin A/ cdk2 in the G2 arrested cells impairs the viability of these cells. A similar ®nding was reported with induced cdk2AF expression during progression from S phase arrest, and resulted in an increased the number of cells with fractured DNA which was qualitatively dierent from the mitotic catastrophe observed with cdc2AF expression (Jin et al., 1996) . These observations provide evidence that blocking the activation of the G2 pool of cyclin A/cdk2 during the G2 arrest assists in maintenance of a stable arrest.
While the activation of cyclin B/cdc2 is sucient to drive entry into mitosis, cyclin B/cdc2 activity is clearly not sucient to ensure proper progression through mitosis. Conditions that activate cyclin B/cdc2 only, for example, bypass of the G2 checkpoint arrest with caeine, over expression of the Ser216 mutant cdc25C, or inappropriate nuclear localisation of cyclin B1/cdc2, result in an increase in the proportion of mitotic catastrophes (Lock et al., 1994; Peng et al., 1997; Jin et al., 1998; Toyoshima et al., 1998) . Thus other factors must contribute to normal G2/M progression and ®delity of mitotic division, and the co-ordinated activation of cyclin A/cdk2 in G2 phase appears to be one of these contributing factors. The apparent lack of ATM involvement in the regulation the cyclin A/ cdk2 activation also suggests that checkpoint pathways that block G2 phase cyclin A/cdk2 activation/activity may be able to impose an ATM-independent block in the subsequent cyclin B/cdc2 activation and entry into mitosis. The mechanism of an ATM-independent arrest requires further investigation, but it may represent a further layer of checkpoint control beyond the established p53-dependent and -independent mechanisms.
Materials and methods
Cell culture
HeLa cells were grown in RPMI 1640 medium supplemented with 5% serum (Serum Supreme, Bio Whittaker), the human melanoma cell lines HT144, A2058 and SK-Mel-13 were maintained in 10% serum, with 100 mg/ml streptomycin and 100 U/ml penicillin, and were tested free of mycoplasma infection. Cells were plated at a density of 2610 6 in 10 cm diameter tissue culture dishes, and treated the following day with either 400 nM etoposide, or exposed to either 10 J m 72 UVC, or 10 Gy ionizing radiation from a 137 Cs source at a dose rate of 3 Gy min
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. In some experiments, cells were initially synchronised by overnight block with 2.5 mM thymidine or 2 mM hydroxyurea. Cultures were released from the block and irradiated or treated with genotoxic agents at 4 ± 6 h after release. Cells were harvested 24 h after genotoxin treatment. Viability was assessed by Trypan blue exclusion, and cells were either ®xed for¯ow cytometric analysis of DNA content, or stored at 7708C for subsequent analysis. Samples were compared to cells in late S/early G2 phase (S/G2) where cultures had been synchronised by an hydroxyurea or thymidine block protocol and harvested 6 h after release, or G2/M phase at 12 h after release from the block (Gabrielli et al., 1997b) . Flow cytometric analysis was performed as described previously (Gabrielli et al., 1997b) .
Immunoblotting and immunoprecipitations
Cell samples were lysed in 1 ml NETN buer (20 mM TrisCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P40) supplemented with 150 mM NaCl, 100 mM sodium vanadate, 10 mM NaF, 0.5 mM PMSF and 5 mg/ml each of leupeptin, aprotinin and pepstatin. Lysates were cleared by centrifugation at 14 000 r.p.m. in a microfuge at 48C, and protein concentrations determined using the Bradford assay. For immunoblotting, 30 mg of each cleared lysate was diluted into SDS ± PAGE sample buer, prior to boiling and electrophoresis through 10% polyacrylamide denaturing gels. Following electrophoresis, resolved proteins were transferred to nitrocellulose membrane by electroblotting. Membranes were then blocked for 2 h in 5% Blotto, prepared in PBS+0.05% Tween 20, then probed with either cyclin A (Pharmingen), p27 (Transduction Laboratories), p21 (Oncogene Science) or cdc2 (Santa Cruz) monoclonal antibodies, or cdk2, cyclin B1, cdc25B, cdc25C, p16 anity puri®ed polyclonal antibodies Wang et al., 1996) , or anti-cdc2 phosphotyrosine 15 antibody (NEB), using appropriate HRPconjugated secondary antibodies and enhanced chemiluminescence detection (NEN).
For immunoprecipitations, 1 mg of each cleared lysate was incubated with the appropriate antibody for 3 h at 48C, with G2 phase cyclin A/cdk2 activity S Goldstone et al simultaneous collection onto protein A-Sepharose beads. Immune complexes were washed four times with NETN buer, and once with PBS prior to resuspension in SDS ± PAGE sample buer, boiling, and analysis of the associated cyclins, cdks, or cdk inhibitor proteins by immunoblotting as above. For cdc2 immunodepletion, 1 mg of cleared lysate was incubated with 5 ± 10 mg of anti-cdc2 antibody overnight. The antibody was removed with 50 ml of protein A-Sepharose. Cyclin A/cdk2 complexes were immunoprecipitated using 0.5 mg of anti-cyclin A antibody as above.
Immune complex kinase assays
Immunoprecipitations were performed as above, except that after the ®nal lysis buer wash, complexes were washed once in kinase buer (20 mM Tris-Cl, pH 7.4, 15 mM MgCl 2 , 1 mM DTT), then resuspended in 30 ml kinase buer with the addition of 0.5 mg/ml histone H1, 200 mM ATP and 5 mCi [ 32 P-g]ATP per reaction. Reactions were run for 15 min at 308C, then terminated by the addition of SDS ± PAGE sample buer, boiled, and electrophoresed through 12% polyacrylamide denaturing gels. Phosphorylated histone H1 was detected by autoradiography of the dried gels, and the extent of phosphorylation in each reaction was quantitated by Phosphorimager analysis.
Cdc25 activation assays
To determine the cdc25 activation potential of cyclin/cdk complexes, cyclin B1, cyclin A or cdk2 immunoprecipitates were prepared as described above, with the following procedural modi®cations: immune complexes were washed four times in NETN as above, followed by a single wash in phosphatase buer (20 mM Tris-Cl, pH 8.3, 50 mM NaCl, 5 mM DDT, 2 mM EDTA, 0.1% Triton X100), then each immunoprecipitate was split into two equal fractions. Each fraction was resuspended in 30 ml of eluted GST-cdc25B (bacterially expressed, puri®ed on glutathione agarose and eluted in phosphatase buer supplemented with 10 mM glutathione as described previously (Gabrielli et al., 1997a) , with and without the addition of sodium vanadate to a ®nal concentration of 0.5 mM (Gabrielli et al., 1997a) . The reactions were incubated for 20 min at 308C and cdc25 activity was then inhibited by the addition of sodium vanadate to a ®nal concentration of 0.5 mM to those reactions not already run in the presence of vanadate. Twenty-®ve ml of kinase buer supplemented with histone H1, ATP and [ 32 P-g] ATP as above was then added to each reaction, and incubations continued for a further 15 min at 308C. Reactions were then terminated by the addition of SDS ± PAGE sample buer, boiled, and processed and quantitated as above.
Construction of mammalian expression vectors
Full length cdc25B2 and cdc25B3 were tagged at the Nterminus with a myc epitope and subcloned into the mammalian expression vector pUCSRa to produce pUCSRa-myccdc25B as described previously (Forrest et al., 1999) . pIREScdk2 wild type (wt) and pIREScdk2AF (mutation of Thr14 and Tyr15 to Ala and Phe respectively ) were constructed by subcloning the 900 bp BamHI ± EcoRI fragment of cdk2wt and cdk2AF plasmids into EcoRI ± NotI digested pIRES puro in a two stage process, ligating the EcoRI ends ®rst, then blunting the free NotI and BamHT ends with T4DNA polymerase, followed by ligation. pIREScdc25B2 CR/SK was constructed by cloning the NotI ± ApaI insert from pUCSRa-myccdc25B2 into the NotI/EcoRI sites of pIRESpuro, ligating the NotI ends ®rst, then blunting the free ApaI and EcoRI ends followed by ligation to regenerate a circular vector.
Transfections
For transfection of the various cdc25 constructs into checkpoint-delayed cells, 5610
6 HeLa cells were plated out, then treated with the various damaging agents as described. Twenty-four hours post-treatment, cells were transfected with 10 mg of the relevant plasmid: pUCSRa (empty vector control), or pUCSRa containing either myc-tagged wild-type or CR/SK mutant versions of cdc25B2 and cdc25B3, or cdc25C. Nocodazole (0.5 mg/ml) was added after 2 h and cells were harvested at 6 h post-transfection for biochemical analysis. For experiments on the eect of dominant negative cdc25B, 5610 6 asynchronously growing HeLa cells were transfected with 10 mg either pIRES puro (empty vector control) or pIREScdc25B2-CR/SK and 24 h later, transfectants were selected by the addition of 10 mg/ml puromycin to the culture medium. After a further 24 h in culture, adherent cells were harvested for analysis of their DNA content, and for biochemical characterization as described.
Either empty vector, cdk2 wt and cdk2AF (pIRES vectors, 10 mg) were transfected into 5610 6 asynchronously growing HeLa cells, and 8 h post-transfection cells were treated with the DNA damaging agents as described above, and cultured for a further 24 h. Cells were then harvested and subjected to two dimensional FACS analysis, identifying the cdk2 over expressing cells by their increased immuno¯uorescent signal after staining with a anti-cdk2 antibody and¯uorescence-conjugated secondary antibody, and the gated over expressors analysed for their DNA content by propidum iodide staining .
